Johnson & Johnson: Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer

Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients New findings from this investigational study build on the strength ...
NerdWallet

American Express Platinum Review: Top-Notch Lounge Access, Big Credits

The lounge access is unparalleled, and the other statement credits can offer tremendous value — but only if you actually use them. Otherwise, the hefty annual fee is hard to justify.

KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)

KEYTRUDA is indicated for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then ...
The Malaysian Reserve

Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer

Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients New findings from this investigational study build on the ...
UroToday

ESMO 2025: Optimized Use of Endocrine Therapies and Chemotherapies in mCRPC

Among 804 androgen receptor pathway inhibitor-experienced mCRPC patients, 459 patients (57.1%) received another androgen receptor pathway inhibitor as their index therapy and 192 (23.9%) received ...